Pharmacogenetics of methotrexate: Toxicity among marrow transplantation patients varies with the methylenetetrahydrofolate reductase C677T polymorphism

Blood

Volumn 98, Issue 1, 2001, Pages 231-234

  Ulrich, Cornelia M ^a,b   Yasui, Yutaka ^a,b   Storb, Rainer ^a,b   Schubert, Mark M ^a,b   Wagner, John L ^a,b   Bigler, Jeannette ^a,b   Ariail, Kiley S ^a,b   Keener, Cassie L ^a,b   Li, Sue ^a,b   Liu, Hao ^a,b   Farin, Federico M ^a,b   Potter, John D ^a,b  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); ANTINEOPLASTIC ANTIMETABOLITE; BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; METHOTREXATE;

ADULT; ARTICLE; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; BONE MARROW TRANSPLANTATION; CANCER CHEMOTHERAPY; CHRONIC MYELOID LEUKEMIA; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; GRAFT VERSUS HOST REACTION; HUMAN; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; PHARMACOGENETICS; PRIORITY JOURNAL; SURVIVAL RATE; THROMBOCYTE COUNT; TREATMENT OUTCOME;

EID: 0035412398     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V98.1.231     Document Type: Article

References (25)

1. Chu E, Allegra C. Antifolates. In: Chabner B, Longo D, eds. Cancer Chemotherapy and Biotherapy. 2nd ed. Philadelphia, PA: Lippincott-Raven; 1996:109-148.
2. Storb R, Deeg HJ, Whitehead J, et al. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. N Engl J Med. 1986;314:729-735.
3. Baggott JE, Vaughn WH, Hudson BB. Inhibition of 5-aminoimidazole-4-carboxamide ribotide transformylase, adenosine deaminase and 5′-adenylate deaminase by polyglutamates of methotrexate and oxidized folates and by 5-aminoimidazole-4-carboxamide riboside and ribotide. Biochem J. 1986;236:193-200.
4. Chu E, Drake JC, Boarman D, Baram J, Allegra CJ. Mechanism of thymidylate synthase inhibition by methotrexate in human neoplastic cell lines and normal human myeloid progenitor cells. J Biol Chem. 1990;265:8470-8478.
5. Frosst P, Blom HJ, Milos R, et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase [letter]. Nat Gen. 1995;10:111-113.
6. Skibola CF, Smith MT, Kane E, et al. Polymorphisms in the methylenetetrahydrofolate reductase gene are associated with susceptibility to acute leukemia in adults. Proc Natl Acad Sci U S A. 1999;96:12810-12815.
7. Ma J, Stampfer MJ, Giovannucci E, et al. Methylenetetrahydrofolate reductase polymorphism, dietary interactions, and risk of colorectal cancer. Cancer Res. 1997;57:1098-1102.
8. Chen J, Giovannucci E, Kelsey K, et al. A methylenetetrahydrofolate reductase polymorphism and the risk of colorectal cancer. Cancer Res. 1996;56:4862-4864.
9. Ulrich C, Kampman E, Bigler J, et al. Colorectal adenomas and the C677T MTHFR polymorphism: evidence for gene-environment interaction? Cancer Epidemiol Biomarkers Prev. 1999;8:659-668.
10. Slattery ML, Potter JD, Samowitz W, Schaffer D, Leppert M. Methylenetetrahydrofolate reductase, diet, and risk of colon cancer. Cancer Epidemiol Biomarkers Prev. 1999;8:513-518.
11. Shaw GM, Rozen R, Finnell RH, Wasserman CR, Lammer EJ. Maternal vitamin use, genetic variation of infant methylenetetrahydrofolate reductase, and risk for spina bifida. Am J Epidemiol. 1998;148:30-37.
12. Ou CY, Stevenson RE, Brown VK, et al. 5,10-Methylenetetrahydrofolate reductase genetic polymorphism as a risk factor for neural tube defects. Am J Med Genet. 1996;63:610-614.
13. Kluijtmans LA, Kastelein JJ, Lindemans J, et al. Thermolabile methylenetetrahydrofolate reductase in coronary artery disease. Circulation. 1997;96:2573-2577.
14. Thomas ED, Clift RA, Fefer A, et al. Marrow transplantation for the treatment of chronic myelogenous leukemia. Ann Intern Med. 1986;104:155-163.
15. Clift RA, Buckner CD, Thomas ED, et al. Marrow transplantation for chronic myeloid leukemia: a randomized study comparing cyclophosphamide and total body irradiation with busulfan and cyclophosphamide. Blood. 1994;84:2036-2043.
16. Hansen JA, Gooley TA, Martin PJ, et al. Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia. N Engl J Med. 1998;338:962-968.
17. Schubert MM, Williams BE, Lloid ME, Donaldson G, Chapko MK. Clinical assessment scale for the rating of oral mucosal changes associated with bone marrow transplantation: development of an oral mucositis index. Cancer. 1992;69:2469-2477.
18. Selhub J, Miller JW. The pathogenesis of homocysteinemia: interruption of the coordinate regulation by S-adenosylmethionine of the remethylation and transsulfuration of homocysteine. Am J Clin Nutr. 1992;55:131-138.
19. Bagley PJ, Selhub J. A common mutation in the methylenetetrahydrofolate reductase gene is associated with an accumulation of formylated tetrahydrofolates in red blood cells. Proc Natl Acad Sci U S A. 1998;95:13217-13220.
20. Sonis ST. Mucositis as a biological process: a new hypothesis for the development of chemotherapy-induced stomatotoxicity. Oral Oncol. 1998;34:39-43.
21. Harmon DL, Woodside JV, Yarnell JW, et al. The common "thermolabile" variant of methylene tetrahydrofolate reductase is a major determinant of mild hyperhomocysteinaemia. QJM. 1996;89:571-577.
22. 12, homocyst(e)ine, and colorectal cancer risk. Cancer Epidemiol Biomarkers Prev. 1999;8:825-829.
23. Molloy AM, Daly S, Mills JL, et al. Thermolabile variant of 5,10-methylenetetrahydrofolate reductase associated with low red-cell folates: implications for folate intake recommendations. Lancet. 1997;349:1591-1593.
24. Roses AD. Pharmacogenetics and the practice of medicine. Nature. 2000;405:857-865.
25. Yu C, Seidel K, Nash RA, et al. Synergism between mycophenolate mofetil and cyclosporine in preventing graft-versus-host disease among lethally irradiated dogs given DLA-nonidentical unrelated marrow grafts. Blood. 1998;91:2581-2587.